文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

治疗药物监测改善结核治疗结局:临床研究范围综述

Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies.
PubMed 文献 · Clin Pharmacokinet · 2026-01-21

该范围综述系统检索截至2025年5月3日的文献,纳入来自10个国家的31项观察性研究,评估TDM对药物敏感或耐药结核患者治疗结局、不良事件及替代指标的影响。目前尚无已发表的TDM实施临床试验(两项正在进行)。观察性数据显示TDM与培养转阴更快、疗程更短及不良事件更少相关,但终末治疗结局无统计学显著差异,仍需设计良好的对照研究验证。

要点

  • 观察性研究提示TDM与培养转阴更快(平均34天 vs 49天)相关
  • TDM组平均疗程32周,短于非TDM组的36周
  • 两组终末治疗成功率均高(67%–100%),但无统计学显著差异

核心结论

  • 观察性数据显示结核治疗中TDM与疗效改善及不良事件减少相关,但需设计良好的对照研究减少偏倚,才能支持其常规应用。

研究设计与样本

  • 范围综述,遵循PRISMA范围综述指南,系统检索PubMed、Embase、Web of Science、ClinicalTrials.gov及WHO临床试验注册库,检索截至2025年5月3日。
  • 初筛5820项研究,最终纳入来自10个国家的31项研究,均为观察性研究,无已发表的TDM实施临床试验,另有2项正在进行。

主要发现

  • 与非TDM组相比,TDM与培养转阴更快相关(平均34天 vs 49天)。
  • 与非TDM组相比,TDM与疗程更短相关(平均32周 vs 36周),且不良事件更少。
  • 所有纳入研究报告的治疗成功率均较高(67%–100%),但TDM组与非TDM组在治疗结束时结局无统计学显著差异。
  • 所有纳入研究均推荐依据TDM进行剂量调整,尽管结果存在异质性。

临床怎么用

  • 对结核患者可考虑依据TDM结果进行个体化剂量调整,以促进培养转阴、缩短疗程并减少不良事件。
  • 鉴于现有证据以观察性研究为主且终末结局差异不显著,TDM尚不宜作为所有结核患者的常规推荐,应结合个体情况权衡。

局限性

  • 纳入研究均为观察性研究,缺乏已发表的随机对照试验,存在潜在偏倚。
  • 各研究结果存在异质性,TDM与终末治疗结局的关系尚无统计学显著差异。
  • 检索截至2025年5月3日,相关临床试验尚在进行中,证据仍在积累。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic drug monitoring (TDM) is a tool used for dose optimization to achieve therapeutic concentrations associated with improved outcomes. However, evidence supporting its benefits for tuberculosis (TB) treatment remains limited. This scoping review evaluated clinical studies on TDM and its impact on TB treatment outcomes. METHODS: A scoping review was performed using a systematic search in PubMed, Embase, Web of Science, ClinicalTrials.gov, and the World Health Organization (WHO) Clinical Trials Registry for interventional and observational studies published until 3 May 2025. We included studies evaluating TDM in adults or children treated for drug-susceptible or drug-resistant TB at any setting worldwide, which reported treatment outcomes, adverse events, or clinical/microbiological surrogate markers. The PRISMA guidelines for scoping reviews were followed to report the findings. RESULTS: Of the 5820 studies screened by title and abstract, 31 studies from 10 countries were eligible for inclusion in this review. No published clinical trials on the implementation of TDM were identified, although two are currently ongoing. Overall, compared with the non-TDM group, TDM was associated with faster culture conversion (mean 34 versus 49 days), shorter treatment duration (mean 32 versus 36 weeks) and fewer adverse events. Although all included studies reported high treatment success rates (ranging from 67% to 100%), no statistically significant differences were observed in end-of-treatment outcomes between TDM and non-TDM groups. Dose adjustments guided by TDM were recommended by all included studies, despite variability in results. CONCLUSIONS: Observational data suggest that TDM in TB treatment was associated with improved effectiveness and fewer adverse events. However, further investigation through well-controlled studies is needed to minimize potential bias and justify its routine use.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Noeriman AR, Sumarheni S, Hasanah AN, et al. Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies. Clin Pharmacokinet. 2026. PMID: 41566098. doi:10.1007/s40262-025-01609-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。